多發性骨髓瘤市場 - 全球及區域分析：按國家和地區 - 分析與預測（2025-2035）

全球多發性骨髓瘤市場分析與預測：2025-2035

多發性骨髓瘤是一種在骨髓產生抗體的漿細胞中發展出來的癌症。

在多發性骨髓瘤中，這些漿細胞會癌變且不受控制地生長，擠佔健康的血球，導致骨質疏鬆、貧血、腎臟損傷和免疫力減弱等併發症。此疾病的主要特徵之一是產生一種名為M蛋白的異常蛋白質，這種蛋白質會在血液和尿液中積聚，並可能對各種器官造成損害，尤其是腎臟。

多發性骨髓瘤的症狀通常包括骨骼疼痛、疲勞、反覆性行為感染和不明原因的體重減輕。診斷通常透過血液和尿液檢查檢查、骨髓切片檢查以及X光和MRI等影像學檢查進行。多發性骨髓瘤目前無法治愈，但包括化療、免疫療法和嵌合抗原受體-T細胞療法在內的治療方法的進步，已經改善了患者的預後，更好地控制了症狀，並延長了生存期。然而，患者通常需要持續治療來控制病情並防止復發。

多發性骨髓瘤市場的主要驅動力之一是對創新標靶治療的需求不斷成長。隨著對多發性骨髓瘤的分子和遺傳機制的深入了解，對能夠滿足復發和難治性多發性骨髓瘤患者獨特需求的療法的需求日益成長。與傳統治療方法相比，CAR-T 細胞療法、雙特異性抗體和單株抗體等免疫療法獲得了顯著的吸引力，因為它們提供了更有效、個人化和毒性更小的治療選擇。這些療法不僅提高了存活率，還提高了患者的生活品質，從而推動了對此類先進療法的需求。此外，隨著全球多發性骨髓瘤發生率的上升，尤其是人口老化，對控制疾病和延長預期壽命的新治療方案的需求變得更加迫切，這進一步推動了多發性骨髓瘤市場的成長。

儘管多發性骨髓瘤市場正在成長，但仍有許多挑戰阻礙其發展。其中最主要的挑戰之一是高昂的治療費用。 CAR-T細胞療法、雙特異性抗體和單株抗體等先進治療方法價格極為昂貴，每次治療通常高達數十萬美元。這給許多患者，尤其是低收入和開發中地區患者，帶來了巨大的治療障礙，因為這些地區的醫療保健系統可能無法充分支持這些療法。

此外，抗治療性也是一大挑戰。多發性骨髓瘤患者通常會經歷復發，並隨著時間的推移對初始治療產生抗藥性。這意味著患者可能需要多輪治療，每次都需要不同的或更高強度的治療方案。抗藥性的產生會降低現有治療方法的有效性，因此需要開發新的治療方法來克服這個問題。

此外，化療和免疫療法等積極治療的副作用會嚴重影響患者的生活品質。許多患者會出現嚴重的副作用，包括疲勞、骨痛、噁心和感染風險，不僅增加了治療方法的複雜性，也降低了患者的依從性。

最後，由於多發性骨髓瘤通常在晚期才被診斷出來，早期發現仍然是一項挑戰。由於缺乏明顯的早期症狀，醫護人員難以在病情進展前發現，這可能導致預後不良。這些挑戰凸顯了對更有效、更低成本的治療方法、更先進的診斷技術以及更好的患者治療期間管理策略的需求。

全球多發性骨髓瘤市場競爭激烈，強生公司（楊森製藥公司）、賽諾菲公司、艾伯維公司、百時美施貴寶公司、武田製藥有限公司、輝瑞公司、Karyopharm Therapeutics Inc.、Cellectar Biosciences, Inc. 和 BioLineRx Ltd. 等主要參與者推動著創新和市場成長。這些公司在開發免疫療法、CAR-T 細胞療法、雙特異性抗體和蛋白酶體抑制劑等新型治療方法方面處於主要企業，這些療法已顯著改善患者的治療效果。透過對研發的策略性投資、擴大產品系列和擴大全球獲得最先進治療的管道，這些產業領導者正在塑造多發性骨髓瘤治療的未來，為市場動態成長做出貢獻。此外，他們對個人化醫療和聯合治療的關注正在改變治療格局，為復發/難治性多發性骨髓瘤患者提供更有針對性和更有效的選擇。

市場區隔:

細分一：按地區

• 北美洲
• 歐洲
• 亞太地區

全球多發性骨髓瘤市場正經歷重大變革時期，新興趨勢正在重塑治療模式，並推動多發性骨髓瘤市場的成長。最顯著的趨勢之一是向免疫療法的轉變，例如嵌合抗原受體T細胞療法、雙特異性抗體和單株抗體，這些療法為復發性或難治性多發性骨髓瘤患者提供了更有針對性、更有效的治療。與傳統化療相比，這些治療方法帶來了更高的緩解率和更長的存活期，徹底改變了疾病的治療方式。

另一個重要趨勢是個人化醫療日益受到重視，即根據患者的基因組成和疾病特徵制定個人化治療方法。這種方法可以提高治療的有效性和精準性，減少副作用，並改善患者的預後。預計未來使用基因檢測和生物標記物來指導治療方法決策將更加普及，從而改善治療方案的最佳化。

此外，聯合治療正在加速興起，該療法將免疫調節藥物 (IMiD)、蛋白酶體抑制劑和標靶治療相結合，以增強治療效果。這些方案提供了更全面的治療方案，尤其適用於對單一藥物治療產生抗藥性的患者。

此外，液態切片、次世代定序和生物標記分析等診斷技術的進步使得多發性骨髓瘤能夠更早發現，從而及時介入並改善患者預後。隨著早期診斷的普及，早期治療市場將持續擴大。

亞太和拉丁美洲等地區醫療保健可近性的改善和醫療基礎設施的建設，正在推動對先進療法的需求。這些趨勢，加上多發性骨髓瘤治療領域持續進行的臨床研究和技術創新，正在塑造多發性骨髓瘤市場的未來，並提供新的成長機會。

本報告研究了全球多發性骨髓瘤市場，概述了市場以及國家和地區趨勢以及參與市場的公司概況。

目錄

執行摘要

第1章全球多發性骨髓瘤市場：產業展望

• 介紹
• 市場趨勢
• 法律規範
• 流行病學分析
• 臨床試驗分析
• 市場動態

2. 2023-2035 年全球多發性骨髓瘤市場（按地區）

• 北美洲
• 歐洲
• 亞太地區

3. 全球多發性骨髓瘤市場：競爭格局與公司概況

• 關鍵策略和發展
  • 合併與收購
  • 協同活動
  • 業務擴展和資金籌措
  • 產品發布和核准
  • 其他活動
• 公司簡介
  • Sanofi SA
  • Karyopharm Therapeutics Inc.
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • Cellectar Biosciences, Inc.
  • BioLineRx Ltd.
  • Aduro Biotech, Inc.
  • Johnson & Johnson (Janssen Pharmaceuticals, Inc.)

第4章調查方法

Global Multiple Myeloma Market, Analysis and Forecast: 2025-2035

Multiple Myeloma is a type of cancer that develops in the plasma cells of the bone marrow, which are responsible for producing antibodies. In multiple myeloma, these plasma cells become cancerous and proliferate uncontrollably, crowding out normal blood cells. This leads to several complications, including weakened bones, anemia, kidney damage, and a weakened immune system. One of the key hallmarks of the disease is the production of abnormal proteins called M-proteins, which can accumulate in the blood or urine and cause damage to various organs, particularly the kidneys.

Symptoms of multiple myeloma often include bone pain, fatigue, recurrent infections, and unexplained weight loss. Diagnosis is typically made through blood tests, urine tests, bone marrow biopsy, and imaging such as X-rays or MRI. While multiple myeloma is currently incurable, advancements in treatment, including chemotherapy, immunotherapy, and CAR T-cell therapy, have improved patient outcomes, allowing for better management of symptoms and extended survival. However, patients often require continuous treatment to manage the disease and prevent relapse.

One of the key drivers of the multiple myeloma market is the increasing demand for innovative and targeted therapies. As the understanding of the disease's molecular and genetic mechanisms deepens, there is a growing need for treatments that can address the specific needs of patients with relapsed and refractory multiple myeloma. Immunotherapies, such as CAR T-cell therapies, bispecific antibodies, and monoclonal antibodies, are gaining significant traction as they offer more effective, personalized, and less toxic treatment options compared to traditional therapies. These therapies not only improve survival rates but also enhance the quality of life for patients, fuelling the demand for such advanced treatments. Additionally, as the global incidence of multiple myeloma rises particularly with an aging population the need for novel treatment options to manage the disease and extend life expectancy is becoming more urgent, further propelling multiple myeloma market growth.

Despite the growth of the Multiple Myeloma market, several challenges continue to hinder its progress. One of the primary challenges is the high cost of treatment. Advanced therapies such as CAR T-cell therapy, bispecific antibodies, and monoclonal antibodies can be extremely expensive, often costing hundreds of thousands of dollars per treatment. This poses a significant barrier to access for many patients, particularly in low-income or developing regions where healthcare systems may not be able to fully support these therapies.

Additionally, treatment resistance is another major challenge. Multiple myeloma patients often experience relapses, and the disease can become resistant to initial therapies over time. This means that patients may need multiple rounds of treatment, with each round potentially involving different or more intensive therapies. The development of drug resistance reduces the effectiveness of existing treatments, creating a need for new therapies that can overcome this issue.

Furthermore, side effects from aggressive treatments, including chemotherapy and immunotherapy, can significantly impact a patient's quality of life. Many patients experience severe side effects such as fatigue, bone pain, nausea, and infection risk, which can complicate treatment regimens and reduce patient compliance.

Finally, early detection remains a challenge, as multiple myeloma is often diagnosed at an advanced stage. The absence of clear early symptoms makes it difficult for healthcare providers to catch the disease before it progresses, which can lead to a poorer prognosis. These challenges underscore the need for more effective, less costly treatments, improved diagnostic techniques, and better management strategies for patients throughout their treatment journey.

The global Multiple Myeloma market is highly competitive, with several leading companies driving innovation and market growth, such as Johnson & Johnson (Janssen Pharmaceuticals, Inc.), Sanofi S.A., AbbVie Inc., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Pfizer Inc., Karyopharm Therapeutics Inc., Cellectar Biosciences, Inc., and BioLineRx Ltd. These companies are at the forefront of developing novel therapies including immunotherapies, CAR T-cell treatments, bispecific antibodies, and proteasome inhibitors, which are significantly improving patient outcomes. Through strategic investments in research and development (R&D), expanding product portfolios, and increasing global access to cutting-edge treatments, these industry leaders are shaping the future of multiple myeloma care and contributing to the dynamic growth of the market. Additionally, their efforts in personalized medicine and combination therapies are transforming the treatment landscape, providing more targeted and effective options for relapsed/refractory multiple myeloma patients.

Multiple Myeloma Market Segmentation:

Segmentation 1: by Region

• North America
• Europe
• Asia-Pacific

The global Multiple Myeloma market is undergoing significant transformation, fueled by emerging trends that are reshaping treatment paradigms and driving multiple myeloma market growth. One of the most notable trends is the shift towards immunotherapy, including CAR T-cell therapy, bispecific antibodies, and monoclonal antibodies, which offer more targeted and effective treatments for patients with relapsed or refractory multiple myeloma. These therapies are revolutionizing the way the disease is managed, providing higher rates of remission and long-term survival compared to traditional chemotherapy.

Another key trend is the increasing focus on personalized medicine, where therapies are tailored based on a patient's genetic makeup and disease characteristics. This approach ensures that treatments are more effective and precise, reducing side effects and improving patient outcomes. The use of genetic testing and biomarkers to guide treatment decisions is expected to become more widespread, further optimizing care.

The rise of combination therapies is also gaining momentum, with the use of immunomodulatory drugs (IMiDs), proteasome inhibitors, and targeted therapies in combination to enhance treatment efficacy. These regimens offer a more comprehensive approach, particularly for patients who have developed drug resistance to single-agent treatments.

Additionally, advancements in diagnostic technologies such as liquid biopsy, next-generation sequencing, and biomarker profiling are enabling earlier detection of multiple myeloma, leading to timely interventions and better patient outcomes. As early diagnosis becomes more prevalent, the market for early-stage therapies will continue to expand.

Finally, global expansion into emerging markets is another driving force, as improving healthcare access and the growing healthcare infrastructure in regions such as Asia-Pacific and Latin America lead to increased demand for advanced treatments. These trends, alongside continued clinical research and innovation in the treatment of multiple myeloma, are shaping the future of the multiple myeloma market and providing new opportunities for growth.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Multiple Myeloma Market: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Epidemiology Analysis
• 1.5 Clinical Trial Analysis
• 1.6 Market Dynamics
  • 1.6.1 Impact Analysis
  • 1.6.2 Market Drivers
  • 1.6.3 Market Challenges
  • 1.6.4 Market Opportunities

2. Global Multiple Myeloma Market (Region), ($Billion), 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Multiple Myeloma Market, by Country
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Multiple Myeloma Market, by Country
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 U.K.
      • 2.2.3.1.3 France
      • 2.2.3.1.4 Italy
• 2.3 Asia Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia Pacific Multiple Myeloma Market, by Country
      • 2.3.3.1.1 China
      • 2.3.3.1.2 Japan

3. Global Multiple Myeloma Market: Competitive Landscape and Company Profiles

• 3.1 Key Strategies and Development
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Business Expansions and Funding
  • 3.1.4 Product Launches and Approvals
  • 3.1.5 Other Activities
• 3.2 Company Profiles
  • 3.2.1 Sanofi S.A.
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Top Competitors
    • 3.2.1.4 Target Customers/End-Users
    • 3.2.1.5 Key Personnel
    • 3.2.1.6 Analyst View
  • 3.2.2 Karyopharm Therapeutics Inc.
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Top Competitors
    • 3.2.2.4 Target Customers/End-Users
    • 3.2.2.5 Key Personnel
    • 3.2.2.6 Analyst View
  • 3.2.3 AbbVie Inc.
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Top Competitors
    • 3.2.3.4 Target Customers/End-Users
    • 3.2.3.5 Key Personnel
    • 3.2.3.6 Analyst View
  • 3.2.4 Takeda Pharmaceutical Company Limited
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products / Product Portfolio
    • 3.2.4.3 Top Competitors
    • 3.2.4.4 Target Customers/End-Users
    • 3.2.4.5 Key Personnel
    • 3.2.4.6 Analyst View
  • 3.2.5 Bristol-Myers Squibb Company
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products / Product Portfolio
    • 3.2.5.3 Top Competitors
    • 3.2.5.4 Target Customers/End-Users
    • 3.2.5.5 Key Personnel
    • 3.2.5.6 Analyst View
  • 3.2.6 Pfizer Inc.
    • 3.2.6.1 Overview
    • 3.2.6.2 Top Products / Product Portfolio
    • 3.2.6.3 Top Competitors
    • 3.2.6.4 Target Customers/End-Users
    • 3.2.6.5 Key Personnel
    • 3.2.6.6 Analyst View
  • 3.2.7 Cellectar Biosciences, Inc.
    • 3.2.7.1 Overview
    • 3.2.7.2 Top Products / Product Portfolio
    • 3.2.7.3 Top Competitors
    • 3.2.7.4 Target Customers/End-Users
    • 3.2.7.5 Key Personnel
    • 3.2.7.6 Analyst View
  • 3.2.8 BioLineRx Ltd.
    • 3.2.8.1 Overview
    • 3.2.8.2 Top Products / Product Portfolio
    • 3.2.8.3 Top Competitors
    • 3.2.8.4 Target Customers/End-Users
    • 3.2.8.5 Key Personnel
    • 3.2.8.6 Analyst View
  • 3.2.9 Aduro Biotech, Inc.
    • 3.2.9.1 Overview
    • 3.2.9.2 Top Products / Product Portfolio
    • 3.2.9.3 Top Competitors
    • 3.2.9.4 Target Customers/End-Users
    • 3.2.9.5 Key Personnel
    • 3.2.9.6 Analyst View
  • 3.2.10 Johnson & Johnson (Janssen Pharmaceuticals, Inc.)
    • 3.2.10.1 Overview
    • 3.2.10.2 Top Products / Product Portfolio
    • 3.2.10.3 Top Competitors
    • 3.2.10.4 Target Customers/End-Users
    • 3.2.10.5 Key Personnel
    • 3.2.10.6 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Multiple Myeloma Market (by Region), $Billion, 2024 and 2035
• Figure: Global Multiple Myeloma Market Key Trends, Analysis

List of Tables

• Table: Global Multiple Myeloma Market Dynamics, Impact Analysis
• Table: Global Multiple Myeloma Market (by Region), $Billion, 2024-2035